Eli Lilly has highlighted what it calls the "societal obligation" surrounding GLP-1 medications, according to STAT News. The company's comments come as GLP-1 drugs have gained significant attention for their effectiveness in treating diabetes and promoting weight loss.
GLP-1 receptor agonists have become among the most sought-after medications in recent years, with drugs like Ozempic and Wegovy capturing widespread public interest. These medications work by mimicking hormones that regulate blood sugar and slow digestion, leading to weight loss in many patients.